Isolated primary CNS lymphoma after liver transplantation for autoimmune hepatitis: A case report

Authors

Alaa Zayed, Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, PO Box 7, Nablus, 00970, Palestine. alaa.altaweel2013@gmail.com.
Qusay Abdoh, Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, PO Box 7, Nablus, 00970, Palestine.
Asmaa Sarama, Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, PO Box 7, Nablus, 00970, Palestine.
Abdalhakim Shubietah, Advocate Health - MidwestFollow

Recommended Citation

Zayed A, Abdoh Q, Sarama A, Shubietah A. Isolated primary CNS lymphoma after liver transplantation for autoimmune hepatitis: a case report. BMC Neurol. 2024;24(1):305. Published 2024 Aug 30. doi:10.1186/s12883-024-03832-8

Affiliations

Advocate Illinois Masonic Medical Center

Abstract

Post-transplantation primary central nervous system lymphoma (PT-PCNSL) is a rare neoplasm that occurs in immunocompromised patients. It can manifest months or years after transplantation, presenting with various neurological symptoms. A 64-year-old woman, who had received a liver transplant due to autoimmune hepatitis, presented with generalized weakness, headache, and confusion. Further investigation revealed multiple ring-enhancing lesions in the right frontal and temporoparietal regions on brain MRI. A brain biopsy confirmed the diagnosis of PT-PCNSL. This case underscores the importance of considering PT-PCNSL in the differential diagnosis of contrast-enhancing brain lesions in post-transplant patients. Timely recognition of PT-PCNSL is crucial for appropriate management and improved outcomes. To the best of our knowledge, this report describes the first instance of isolated CNS lymphoma in a liver transplant recipient, due to autoimmune hepatitis, successfully brought to complete remission with a rituximab-methotrexate regimen.

Document Type

Article

PubMed ID

39215224